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Purpose: A surgical resection is a potentially curative treatment for
non-small cell lung cancer (NSCLC). This study investigated the
time trends of the surgical outcome in patients with NSCLC.
Methods: This study clinicopathologically evaluated 1487 patients
who had undergone a resection for NSCLC between 1979 and 2008
during the five periods of 1979–1988, 1989–1993, 1994–1998,
1999–2003, and 2004–2008.
Results: The number of patients who underwent a resection during
the five respective periods increased: 167, 261, 248, 382, and 429.
The percentage of pathologic stage IA lung cancers was 16.2, 21.5,
23.0, 38.5, and 52.0% in each period, respectively, and it has risen
rapidly in recent years. The percentage of adenocarcinoma has also
progressively increased during each period: 49.1, 52.1, 54.7, 62.8,
and 69.7%, respectively. The diameter of the tumors resected during
each period was 36, 37, 38, 33, and 26 mm, respectively, showing
that the tumor tended to be diagnosed at an increasingly smaller size.
The postoperative 5-year survival rates during the five periods
improved markedly: 34.1, 44.0, 44.9, 65.4, and 76.5%, respectively.
Patients with pathologic stage IA lung cancer also exhibited increas-
ingly higher 5-year survival rates during the five periods: 70.0, 71.2,
80.4, 89.2, and 88.7%, respectively.
Conclusion: The prognosis of NSCLC patients has remarkably
improved in recent years. The increase in the number of patients
with adenocarcinoma in the early stage is thought to have strongly
contributed to the favorable results. Thus, early diagnosis remains a
key factor for improving the survival of lung cancer patients after
surgical treatment.
Key Words: Time trend, Surgical resection, Non-small cell lung
cancer, Surgical outcome.
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The incidence of lung cancer is still increasing in recentyears, and it is the leading cause of cancer-related mor-
tality in many industrialized countries.1,2 To date, lung cancer
is known to be a treatment-refractory disease, causing more
than 60,000 deaths per year in Japan. The countermeasures to
decrease death caused by lung cancer have become an im-
portant public health issue. The 5-year survival rate in lung
cancer is reported to be 10 to 15% throughout the world,
because most patients present with inoperable advanced dis-
ease.3 On the other hand, an improvement of postoperative
prognosis of non-small cell lung cancer (NSCLC) has been
recently reported.4 A recent increase of peripheral small
adenocarcinoma has led to markedly improve surgical results
in patients with lung cancer resection.5 One possible expla-
nation for the increase of stage IA lung cancer may be
because of the recent advances in imaging techniques, which
facilitate the diagnosis of adenocarcinoma with ground-glass
attenuation.
The current treatment strategy for NSCLC depends
on clinical staging. Surgical resection is the first-line
treatment for stages I to II NSCLC. Approximately 30% of
patients with NSCLC presents with locally advanced dis-
ease. Some stage III patients can possibly benefit from
surgical treatment.6 Patients with microscopic lymph node
metastasis and single-station nodal involvement have a
greater chance for cure even in stage III disease, and
surgery can contribute in combination treatment with che-
motherapy.7 Patients with ipsilateral pulmonary metastasis
without mediastinal lymph node involvement are also
reported to be good candidates for surgical resection.8
These indications of surgical treatment have remained
mostly unchanged for a few decades. However, there have
also been a number of advances in perioperative patient
management, anesthetic management, and intraoperative
surgical management during the last three decades. This
study retrospectively investigated the clinicopathologic
features of NSCLC patients who underwent surgery, and
the time trends of surgical outcome were reviewed.
PATIENTS AND METHODS
The hospital records of 1487 consecutive patients who
underwent a resection of NSCLC between 1979 and 2008
were reviewed. The preoperative assessments included chest
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roentgenography and computed tomography (CT) of the
chest, upper abdomen, and brain. Clinical N2 status was
defined by CT, when a short axis of mediastinal lymph node
was more than 1 cm in diameter. The presence of a lymph
node with a short diameter of more than 1 cm. Bone scintig-
raphy was performed to detect any bone metastasis. Magnetic
resonance imaging of the brain was routinely used after 2001.
Bronchoscopy was routinely performed to obtain a pathologic
diagnosis by transbronchial lung biopsy endobronchial stag-
ing and to evaluate the resection margin. The patients’
records including the clinical data, preoperative examination
results, details of the surgical operation, histopathologic find-
ings, and the tumor, node, metastasis stages of all patients
were also reviewed. The cardiac function was assessed based
on a physical examination, electrocardiography, and transtho-
racic echocardiography. The pulmonary function was evalu-
ated using spirometry and arterial blood gas analysis. A
ventilation perfusion scan was routinely performed to predict
postoperative lung function. Predictive postoperative lung
function was considered as operable if the forced vital capac-
ity and forced expiratory volume in 1 second as percent of
forced vital capacity was greater than 900 and 600 ml/m2,
respectively.
The pulmonary resections were performed by means
of a posterolateral thoracotomy, and recently, video-as-
sisted thoracic surgery was introduced for stage IA dis-
ease. The standard surgical procedure has been a lobec-
tomy with a radical mediastinal node resection for the past
30 years. All resected specimens, including the primary
tumor and resected hilar, and mediastinal lymph nodes
were examined for tumor histology and the extent of
lymph node metastases. The histopathologic findings were
classified according to the World Health Organization
criteria, and the Union Internationale Contra le Cancer
(UICC) tumor, node, metastasis staging system (6th edi-
tion) was used.9,10 Epidural anesthesia was routinely used
to reduce postoperative pain and to enable the patients to
clear respiratory secretions through improved coughing
and deeper inspiration.
No patients underwent adjuvant chemotherapy before
2000. In 2001, we started a clinical trial of adjuvant therapy
with carboplatin (CBDCA)  paclitaxel for stages IB, II, and
III patients. Since 2005, we have routinely performed adju-
vant chemotherapy with CBDCA  paclitaxel or CBDCA 
gemcitabine for stages IB, II, and III. No patients were
administered epidermal growth factor receptor-tyrosine ki-
nase inhibitor as an adjuvant therapy. Follow-up information
was obtained from all patients through office visits or tele-
phone interviews with the patient, with a relative, or with
their primary physicians. The patients were evaluated every 3
months by chest roentgenography, and chest CT scan and
bone scintigraphy were obtained every 6 months for the first
2 years after surgery and annually thereafter. The mean
observation time was 3.5 years.
The survival curve was calculated by the Kaplan-Meier
method and compared by using the log-rank test for the
univariate analysis. Categorical variables were compared by
Fisher exact test. The differences were considered to be
significant if the p value was less than 0.05. The Statview V
software program (Abacus Concept, Berkeley, CA) was used
for all statistical analyses.
RESULTS
There were 1487 patients who underwent a resection
for NSCLC between 1979 and 2008, in the Second Depart-
ment of Surgery, University of Occupational and Environ-
mental Health. The time trends of surgical outcome and
clinicopathologic features were evaluated separately during
the periods of 1979–1988, 1989–1993, 1994–1998, 1999–
2003, and 2004–2008, every 5 years except for the first 10
years. There were no patients with tumors detected by mass
screening with low-dose CT. The number of patients who
underwent a resection during these five respective periods
increased as follows: 167, 261, 248, 382, and 429, respec-
tively. The mean age of the patients in each period was 62.9,
64.7, 66.7, 68.2, and 69.6 years, respectively. The proportion
of female patients gradually increased as follows: 26.9, 29.5,
28.2, 33.0, and 37.3%. The percentage of pathologic stage IA
lung cancers in each period was 16.2, 21.5, 23.0, 38.5, and
52.0%, respectively, and it has risen rapidly in recent years
(Figure 1). The percentage of adenocarcinoma increased
during each period as follows: 49.1, 52.1, 54.7, 62.8, and
69.7%, respectively. In contrast, the proportion of squamous
cell carcinoma decreased gradually as follows: 34.7, 36.0,
34.6, 28.5, and 20.5%, respectively. The average percentage
of adenocarcinoma was 52.2% in the former period (1989–
1998), whereas it was 66.5% in the later period (1999–2008),
thus indicating a significant increase (p  0.001) (Figure 2).
The average percentage of squamous cell carcinoma changed
significantly from 36.2 to 24.2% between the former and the
later period (p  0.001). The diameter of tumors during each
period was 36.0, 37.3, 37.9, 33.1, and 26.8 mm, respectively.
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FIGURE 1. Change in the pathologic stage of non-small
cell lung cancer according to the periods. The percentage of
pathologic stage IA lung cancers in each period was 16.2,
21.5, 23.0, 38.5, and 52.0%, respectively. No significant
changes were observed in the proportion of each stage be-
tween 1979 and 1999. However, the incidence of patients
presenting with stage IA disease has risen rapidly since 1999.
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When these groups were divided into the former (1989–
1998) and the latter periods (1999–2008), a significant de-
crease in the tumor size was observed (Figure 3). The history
of cigarette smoking has been available in the patient’s
medical records since 1994. The percentage of never smokers
in the patients with lung cancer was gradually increased
according to the periods: 23% in 1994–1998, 26% in 1999–
2003, and 28% in 2004–2008. Next, the overall survival in
each period was analyzed by the Kaplan-Meier method. The
postoperative 5-year survival rates during the five periods
improved markedly: 34.1, 44.0, 44.9, 65.4, and 76.5%, re-
spectively (Figure 4). The survival rate during 2004–2008
was significantly higher than that of any previous period (p
0.01). Patients with pathologic stage IA lung cancer also
exhibited increasingly higher 5-year survival rates during the
five periods: 70.0, 71.2, 80.4, 89.2, and 88.7%, respectively
(Table 1). The prognosis of stage IA disease in 1999–2003
and 2004–2008 showed a significant improvement in com-
parison with that of previous periods. In each stage, the
survival rate after surgery tends to be improved according to
the successive periods.
DISCUSSION
Lung cancer is known to be one of the treatment-
refractory cancers and remain the leading cause of cancer
death worldwide. It is usually diagnosed at a regionally
advanced or incurable metastatic stage.3 However, early de-
tection of the disease and a curative surgical resection are
considered to be the most important countermeasure to re-
duce mortality because of lung cancer. Recent advances in
imaging diagnostic technology have enabled the detection of
early-stage lung cancer.11 The widespread use of CT scan for
screening of lung cancer or evaluation of other chest disease
may have been associated with such detection of small
peripheral carcinoma. Reflecting such a situation, the im-
proved prognosis was considered to be ascribed to an increase
of female adenocarcinoma (i.e., well-differentiated papillary
adenocarcinoma or a nonmucinous type of bronchiole-alve-
olar carcinoma), which has a low potential for malignancy.12–14
In this study, the survival rates for both periods, namely
1999–2004 and 2004–2008, were significantly better than
the rates for any previous three periods (1979–1998; p 
0.01). Although the overall survival for each period was
analyzed by the Kaplan-Meier method, one problem in this
analysis existed because of the fact that the period in
2004–2008 included many censored cases.
Large-scale surveys regarding the surgical outcome for
lung cancer were conducted by the Japan Joint Committee of
Lung Cancer Registry in 1994 and 1999.15,16 These surveys
showed 5-year survival rates of 51.9 and 60.6%, respectively,
indicating an improved prognosis over those 5 years. The
percentage of stage IA lung cancer increased from 29.7 to
37.5%, and that of adenocarcinoma also increased from 55.7
to 61.7%. These reports were consistent with the current
results. Furthermore, this study demonstrates a remarkable
scaling down of tumor size in the past decade. Screen-
detected and incidentally detected lung cancer have also
increased in recent years.17 Screen-detected lung cancers
are reported to be less advanced, tend to have a smaller
diameter, and more frequently adenocarcinoma.18 The de-
tection before the appearance of symptoms results in a
more favorable postoperative prognosis.19 It is also under-
stood that Will-Rogers phenomenon might be associated
with the improvement in the prognosis. As a result, stage
migration using advanced imaging technology is, thus,
considered to substantially contribute to the achievement
of the favorable surgical results.
The large-scale surveys in 1994 and 1999 revealed
improved survival rates in patients with stage II or III lung
cancer. This may have been because of not only improve-
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FIGURE 3. Comparison of the tumor diameter between the
former and the latter periods. The tumor size at the time of
diagnosis tended to decrease, especially since 1999. When
these groups were divided into the former (1989–1998) and
the latter periods (1999–2008), a significant decrease in the
tumor size was observed.
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FIGURE 2. Comparison of the histologic types between the
former and the latter periods. When these groups were di-
vided into the former (1989–1998) and the latter periods
(1999–2008), the percentage of adenocarcinoma signifi-
cantly increased, when compared between the two periods
(52.2 vs. 66.5%; p  0.001). In contrast, the average per-
centage of squamous cell carcinoma changed significantly
from 36.2 to 24.2% between the former and the latter peri-
ods (p  0.001).
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ments in surgical techniques and postoperative management
but also the effects of postoperative adjuvant chemotherapy
and chemotherapy for recurrent lung cancer by using new
anticancer agents. Several clinical trials demonstrated signif-
icantly longer survival with adjuvant chemotherapy with
platinum-based doublet regimens.20,21 A recent meta-analysis
of pooled individual data from five large trials (n  4584)
revealed a significant improvement in overall survival in
surgery and cisplatin-based adjuvant chemotherapy, in compar-
ison with surgery alone (hazard ratio  0.89, 95% confidence
interval 0.82–0.96; p  0.005).22 The development of new
agents such as vinorelbine, gemcitabine, docetaxel, paclitaxel,
and irinotecan in the 1990s has led to several reports that
chemotherapy improves overall survival significantly in all pa-
tients with advanced or recurrent NSCLC.23 The recent thera-
peutic innovations such as epidermal growth factor receptor-
tyrosine kinase inhibitor and pemetrexed will contribute to the
improvement of postoperative prognosis for recurrent dis-
ease.24–26
The rapidly increasing age is one of the recent features in
the NSCLC patients who underwent surgery. Based on the
progressive aging society in developed countries, the treatment
of elderly people with NSCLC has become a frequent clinical
problem. Advances in perioperative management and anesthetic
management have enabled to perform surgery in safety for
elderly patients. A surgical resection is, therefore, recommended
even for elderly patients after carefully evaluating the tolerability
of surgery from the viewpoint of important organ function such
as heart, brain, liver, and kidney, if the lesion is completely
resectable. A number of investigations reported a survival ben-
efit of surgical treatment in selected elderly people, without any
severe complications.27,28
The prognosis of NSCLC patients has been remarkably
improved in recent years. The increase in the number of
patients with adenocarcinoma in the early stage is thought to
have strongly contributed to the favorable results. Thus, early
diagnosis remains a key factor for improving the survival of
lung cancer patients after surgical treatment.
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